----item----
version: 1
id: {EB62BE8D-FF3C-43D4-B3CB-DA3C7BDB5486}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/09/06/BIO 2015 Dispatches Acorda CEO Cohen to bring passion to BIO chairmanship
parent: {199B8802-DA9B-45D7-BE07-8E7DA944A744}
name: BIO 2015 Dispatches Acorda CEO Cohen to bring passion to BIO chairmanship
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: eb949302-b03c-44df-a380-3f30425f95e0

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 76

BIO 2015 Dispatches: Acorda CEO Cohen to bring 'passion' to BIO chairmanship
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 73

BIO 2015 Dispatches Acorda CEO Cohen to bring passion to BIO chairmanship
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 2313

<p>The board of directors for the Biotechnology Industry Organization (BIO) on 15 June opened its annual meeting in Philadelphia by electing Dr Ron Cohen, president and CEO of Acorda Therapeutics, as the group's new chairman for 2015-16.</p><p>BIO CEO Jim Greenwood noted that Dr Cohen has been an active member of the biotech lobbying organization's board for many years.</p><p>He previously served as chair of BIO's Emerging Companies Section Governing Board and vice chair of group's Health Section Governing Board. </p><p>Dr Cohen is known for his "tremendous passion and a wealth of industry experience," Mr Green said, adding that in the chairman's role, the Acorda chief is expected to "help drive continued growth" for the group and the overall biotechnology industry.</p><p>"The biotech industry is among the most innovative in the world," said Dr Cohen, who founded Acorda in 1995.</p><p>He said he started the Ardsley, New York-based company with a "specific but challenging" mission: to develop therapies that could restore neurological function and improve the lives of people with neurological disorders &ndash; an area Dr Cohen said lacked treatments two decades ago.</p><p>Since then, there's been "impressive progress" for new therapeutic options for people with nervous system disorders, particularly multiple sclerosis, Dr Cohen said. </p><p>Acorda currently markets Ampyra (dalfampridine), a potassium channel blocker, as a therapy to improve walking for people with MS.</p><p>The firm also markets Zanaflex (tizanidine hydrochloride) as a short-acting drug to manage spasticity and Qutenza (capsaicin), a patch product indicated for the management of neuropathic pain associated with postherpetic neuralgia.</p><p>The company's pipeline includes therapies aimed at treating MS, post-stroke walking deficits, Parkinson's disease, epilepsy, neuropathic pain, heart failure and spinal cord injury. </p><p>The BIO board also re-elected Dan Junius, president and CEO of ImmunoGen, as treasurer.</p><p>In addition, 19 directors were elected to serve on BIO's board executive committee for the new term.</p><p><i>Our daily &ldquo;BIO 2015 Dispatches&rdquo; draw on the combined forces of Scrip Intelligence and The Pink Sheet staff, reporting from the Philadelphia meeting.</i></p><p><p><p><p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 241

<p>The board of directors for the Biotechnology Industry Organization (BIO) on 15 June opened its annual meeting in Philadelphia by electing Dr Ron Cohen, president and CEO of Acorda Therapeutics, as the group's new chairman for 2015-16.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 73

BIO 2015 Dispatches Acorda CEO Cohen to bring passion to BIO chairmanship
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150906T160210
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150906T160210
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150906T160210
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC028985
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 76

BIO 2015 Dispatches: Acorda CEO Cohen to bring 'passion' to BIO chairmanship
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{185C14A2-61E1-460C-96C2-EB0D8AB963B0}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 13

Headline News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

358861
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042404Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

eb949302-b03c-44df-a380-3f30425f95e0
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042404Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
